- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07913165
A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy
An Open-Label, Single-Arm, Single-Center Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Refractory to ≥2 Prior Lines of Chemotherapy
This study aims to evaluate the efficacy and safety of TAS-102 combined with nedaplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma who have experienced disease progression after two or more lines of prior chemotherapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Zhenyu Lin
- Telefonnummer: 027-85871982
- E-post: whxhlzy@hust.edu.cn
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Age: 18-75 years;
-
Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
-
Diagnosis: Histologically or pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction;
-
Prior Treatment: Disease progression or failure after receiving second-line or later chemotherapy;
-
TNM Stage: TNM Stage IV (TanyNanyM1);
-
Measurable Disease: Presence of at least one radiologically evaluable lesion per RECIST v1.1 criteria (or other applicable criteria) within 21 days prior to enrollment;
-
Adequate Organ Function: Defined as follows within specified timeframes before enrollment;
-
Hematology:
- Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L
- Platelet count (PLT) ≥ 90 × 10⁹/L
- Hemoglobin (Hb) ≥ 90 g/L
-
Biochemistry:
- Total Bilirubin (TBIL) ≤ Upper Limit of Normal (ULN)
- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 1.5 × ULN
- Alkaline Phosphatase (ALP) ≤ 2.5 × ULN
- Blood Urea Nitrogen (BUN) and Serum Creatinine (Cr) ≤ 1.5 × ULN
- Creatinine Clearance (CrCl) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula)
-
Coagulation:
- International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN
- Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN
-
Cardiac Function:
- Left Ventricular Ejection Fraction (LVEF) ≥ 55% as measured by Echocardiography (ECHO) or Multigated Acquisition Scan (MUGA)
- Corrected QT interval using Fridericia's formula (QTcF) < 470 ms for females and < 450 ms for males on Electrocardiogram (ECG);
-
-
Informed Consent: Voluntarily provide written informed consent prior to any study-specific procedures.
Exclusion Criteria:
-
Prior TAS-102: Previous treatment with TAS-102;
-
Concurrent Anticancer Therapy: Concurrent participation in another clinical trial involving anticancer therapy;
-
Recent Major Surgery: Undergone major surgical procedures within 4 weeks prior to enrollment, or has not fully recovered from such procedures;
-
Significant Cardiac Disease: History or presence of clinically significant cardiac disease, including but not limited to:
- History of congestive heart failure (CHF) or systolic dysfunction (LVEF < 50%).
- High-risk uncontrolled arrhythmias, significant ventricular arrhythmia (e.g., ventricular tachycardia), or high-grade atrioventricular block.
- Angina pectoris requiring anti-anginal medication.
- Clinically significant valvular heart disease.
- ECG evidence of transmural myocardial infarction.
- Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg);
-
General Exclusion: Any other condition that, in the judgment of the Investigator, would make the subject unsuitable for participation in the study or compromise protocol compliance.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: TAS-102 plus nedaplatin
|
TAS-102:35mg/m2(BID, D1-5, D8-12)Q4W, 6 cycles + Nedaplatin:80-100mg/m2 Q4W, 6 cycles |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free survival (PFS)
Tidsram: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to RECIST v1.1 |
Through out the study (up to 2 years)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective response rate (ORR)
Tidsram: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1). |
Through out the study (up to 2 years)
|
|
Disease control rate (DCR)
Tidsram: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to RECIST v1.1 |
Through out the study (up to 2 years)
|
|
Overall survival (OS)
Tidsram: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to RECIST v1.1 |
Through out the study (up to 2 years)
|
|
Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)
Tidsram: Through out the study (up to 2 years)
|
Adverse events will be assessed by investigator(s) according to Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). |
Through out the study (up to 2 years)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TAS-102-GAS
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .